Follow

A new study published in PLOS Global Public Health shows that a short, all-oral, 6-month treatment regimen for drug-resistant can save national governments up to US$740 million annually. This regimen will be included in the new World Health Organization (WHO) guidelines for the treatment of DR-TB, a form of the disease which impacts nearly half a million people each year. Find out more about how the cost of implementing this therapy is potentially 40-90% less expensive than current regimens: journals.plos.org/globalpublic

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.